The effects of group 1 versus group 2 carbapenems on imipenem-resistant Pseudomonas aeruginosa: an ecological study (Q44813223)

6 December 2017

title

The effects of group 1 versus group 2 carbapenems on imipenem-resistant Pseudomonas aeruginosa: an ecological study (English)

1 reference

6 December 2017

main subject

carbapenem antibiotic

0 references

Pseudomonas aeruginosa

object named as

Pseudomonas aeruginosa

1 reference

based on heuristic

inferred from title

beta-lactam resistance

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21683268

4 December 2024

Shiri Navon-Venezia

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21683268

4 December 2024

Yehuda Carmeli

1 reference

6 December 2017

Shiri Klarfeld Lidji

series ordinal

1 reference

6 December 2017

Esther Shabtai

series ordinal

1 reference

6 December 2017

Mitchell J. Schwaber

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21683268

4 December 2024

language of work or name

1 reference

1 July 2011

1 reference

6 December 2017

July 2011

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21683268

full work available at URL

4 December 2024

https://api.elsevier.com/content/article/PII:S0732889311001027?httpAccept=text/xml

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2011.03.009

https://api.elsevier.com/content/article/PII:S0732889311001027?httpAccept=text/plain

4 December 2024

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2011.03.009

Diagnostic Microbiology and Infectious Disease

4 December 2024

published in

1 reference

6 December 2017

1 reference

6 December 2017

1 reference

6 December 2017

page(s)

367-372

1 reference

maintained by WikiProject

6 December 2017

1 reference

Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact.

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2011.03.009

Failure of quality control measures to prevent reporting of false resistance to imipenem, resulting in a pseudo-outbreak of imipenem-resistant Pseudomonas aeruginosa

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2011.03.009

Antecedent treatment with different antibiotic agents as a risk factor for vancomycin-resistant Enterococcus

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2011.03.009

Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2011.03.009

First national surveillance of susceptibility of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. to antimicrobials in Israel.

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2011.03.009

The impact of antimicrobial resistance on health and economic outcomes

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2011.03.009

Surgical site infection in patients submitted to digestive surgery: risk prediction and the NNIS risk index

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2011.03.009

Bowel colonization with vancomycin-resistant enterococci after antimicrobial therapy for intra-abdominal infections: observations from 2 randomized comparative clinical trials of ertapenem therapy

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2011.03.009

Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-tazobactam therapy for intraabdominal infections

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2011.03.009

Bowel colonization with resistant gram-negative bacilli after antimicrobial therapy of intra-abdominal infections: observations from two randomized comparative clinical trials of ertapenem therapy

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2011.03.009

Ertapenem: no effect on aerobic gram-negative susceptibilities to imipenem

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2011.03.009

Introduction of ertapenem into a hospital formulary: effect on antimicrobial usage and improved in vitro susceptibility of Pseudomonas aeruginosa

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2011.03.009

In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends).

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2011.03.009

Differential effects of levofloxacin and ciprofloxacin on the risk for isolation of quinolone-resistant Pseudomonas aeruginosa

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2011.03.009

Selectivity of ertapenem for Pseudomonas aeruginosa mutants cross-resistant to other carbapenems

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2011.03.009

Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use.

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2011.03.009

Reexamining quinolone use in the intensive care unit: use them right or lose the fight against resistant bacteria

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2011.03.009

Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2011.03.009

Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs).

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2011.03.009

“Collateral Damage” from Cephalosporin or Quinolone Antibiotic Therapy

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2011.03.009

Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2011.03.009

Emergence of resistance to imipenem during therapy for Pseudomonas aeruginosa infections.

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2011.03.009

Two decades of imipenem therapy

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2011.03.009

Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2011.03.009

Epidemiological interpretation of antibiotic resistance studies - what are we missing?

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2011.03.009

Ertapenem, the first of a new group of carbapenems

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2011.03.009

The ORION statement: guidelines for transparent reporting of outbreak reports and intervention studies of nosocomial infection

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2011.03.009

Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2011.03.009

Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2011.03.009

4 December 2024

Identifiers

DOI

1 reference

6 December 2017

1 reference